Literature DB >> 28177326

Supracricoid laryngectomy for recurrent laryngeal cancer after chemoradiotherapy: a systematic review and meta-analysis.

C A Leone1, P Capasso1, D Topazio1, G Russo1.   

Abstract

Residual or recurrent laryngeal cancer after irradiation is a difficult clinical problem with a rate that ranges from 13% to 36% of cases. Supracricoid laryngectomy (SCL) with cricohyoidopexy (CHP) or cricohyoidoepiglottopexy (CHEP) provide reliable oncological and functional results for selected primary and recurrent patients with glottic and supraglottic carcinomas. We conducted a systematic review and meta-analysis to assess the oncological and functional outcomes of patients treated with open partial horizontal laryngectomy types IIa and IIb (CHEP, CHP) in terms of the recurrence of squamocellular cancer of the larynx after radiotherapy failure. The databases searched included MEDLINE, PubMed and EMBASE (from January 1990 to December 2015, English language). The meta-analysis was performed with a mixed random effects model using the DerSimonian and Laird method. The heterogeneity was measured with the I2 statistic. Fourteen papers out of 276 were included and comprised a total of 291 patients. The five-year overall survival was 80.2% (CI 0.719-0.885; I2 = 62%; p = 0.003), and the 5-year disease-free survival was 89.5% (CI 0.838-0.952; I2 = 52%; p = 0.022). The indications for SCL after the failure of radiation therapy (RT) were similar to those specified for previously untreated patients. We therefore hypothesised that careful assessment of tumour extension might be responsible for the high 5-year OS and 5-year DFS. The early postoperative recovery outcomes indicated that the mean time until decannulation was 35.6 days (CI 24.3-46.9; I2 = 95%; p < 0.001), and the mean time until nasogastric tube (NGT) or percutaneous endoscopic gastrostomy (PEG) removal was 28.3 days (CI 22.7-33.8; I2 = 86%; p< = 0.001). These data are according to authors who prefer the initial removal of the NGT and the initiation of oral alimentation with a tracheostomy tube to protect and clean the airways and permit the suction of any residual food that might be present. © Copyright by Società Italiana di Otorinolaringologia e Chirurgia Cervico-Facciale, Rome, Italy.

Entities:  

Keywords:  Laryngeal cancer; Meta-analysis; Radiotherapy; Recurrence; Supracricoid laryngectomy

Mesh:

Year:  2016        PMID: 28177326      PMCID: PMC5317122          DOI: 10.14639/0392-100X-1063

Source DB:  PubMed          Journal:  Acta Otorhinolaryngol Ital        ISSN: 0392-100X            Impact factor:   2.124


Introduction

Residual or recurrent laryngeal cancer after irradiation is a difficult clinical problem with a rate that ranges from 13% to 36% -. Although several treatment options exist for patients affected with laryngeal cancer at first presentation , the options for those with recurrent cancer are limited based on the initial treatment received . Cancers that recur after radiation therapy (RT) often exhibit aggressive behaviour, arise in a field in which lymphatic drainage is unpredictable and are associated with poor control rates . Total laryngectomy is a frequently recommended option even for early recurrent cancers after chemoradiotherapy, but this procedure substantially impairs the quality of life primarily due to the permanent tracheostoma and the loss of the voice . Supracricoid laryngectomies (SCLs) were recently classified by the European Laryngological Society as Open Partial Horizontal Laryngectomies Type II, which include reconstructions either by cricohyoidoepiglottopexy (CHEP; renamed OPHL Type IIa) or cricohyoidopexy (CHP; renamed OPHL Type IIb). Both of these procedures provide reliable oncological and functional results for selected primary and recurrent patients with glottic and supraglottic carcinomas -. Several reports regarding the effectiveness of SCLs in terms of survival and functional results considering residual and recurrent cancer have been published. The aim of this systematic review and meta-analysis was to evaluate the pooled oncological and short-term postoperative recovery outcomes of supracricoid laryngectomies with CHEP and CHP in the setting of recurrent laryngeal squamocellular cancer (SCC) after chemoradiotherapy.

Materials and methods

Data sources and searches

We aimed to identify all papers that assessed the oncological and functional outcomes of patients treated with supracricoid laryngectomy for recurrence of SCC of the larynx after RT failure. The databases searched included MEDLINE, PubMed and EMBASE (from January 1990 to December 2015). We applied English language and abstract availability restrictions. Our search included the following keywords: laryngeal cancer, supracricoid laryngectomies, subtotal laryngectomy, cricohyoidopexy, cricohyoidoepiglottopexy, and/or retrospective study, prospective and randomised clinical study.

Selection of studies

Publications were included if they included patients affected with recurrent laryngeal SCC after initial treatment with RT that was salvaged with supracricoid laryngectomy and reported the 5-year overall survival (OS), 5-year disease free survival (DFS) and short-term postoperative recovery outcomes. We included only full published papers and excluded abstracts and reviews. Papers containing inadequately separable oncological or functional data, series that included patients treated with different procedures and those focusing on other topics or other surgical techniques were excluded.

Outcome measures

The primary outcome was 5-year overall survival (OS). The secondary outcomes were 5-year disease-free survival (DFS), short-term postoperative recovery outcomes and 5-year OS and 5-year DFS according to the T stage (early and locally advanced). Short-term postoperative recovery outcomes included the mean time until decannulation and the mean time required for oral feeding restoration, which is expressed as the mean time until nasogastric tube (NGT) or percutaneous endoscopic gastrostomy (PEG) removal. According to T stage, patients were divided into two groups for statistical analysis, i.e., early (rT1-T2) and locally advanced (rT3-T4) groups.

Data extraction

Initial selection was performed via the screening of the titles and abstracts by two pairs of independent reviewers (GR and CAL, PC and DT). For detailed evaluations, fulltext copies of all studies except one (Shenoy et al., 2000) that were possibly relevant were obtained. The data from each study were extracted independently by paired and independent reviewers (GR and CAL, PC and DT) using a pre-standardised data abstraction form. The data extracted from the publications were independently checked for accuracy by two additional reviewers (PC and PD). We resolved any possible disagreements by consensus in consultation with a third reviewer (CAL) when needed.

Quantitative analysis

The meta-analysis was performed with a mixed random effect model using the DerSimonian and Laird method. The results were graphically represented using Forest plots. The proportions and 95% CIs for each outcome were separately calculated for each trial with the grouped data using the intention-to-treat principle. The choice to use the proportions was driven by the design of meta- analysis, which was based on the included studies. The tau2 was used to define the between-studies variance. The P value was set at 0.05. The homogeneity assumption was examined with the Q test with a degree of freedom (df) equal to the number of analysed studies minus 1. The heterogeneity was measured with the I2 statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than chance. The I2 was calculated from the basic results obtained from a typical meta-analysis as I2 = 100% Å ~ (Q – df)/Q, where Q is Cochran's heterogeneity statistic, and df is the degrees of freedom. A value of 0% indicates no observed heterogeneity, and larger values indicate increasing heterogeneity. We performed an "a priori" sub-analysis of the oncological outcomes according to the early (rT1-T2) and locally advanced (rT3-T4) stages of recurrent laryngeal SCC. Next, we performed an "a priori" comparison of the same oncological outcomes between early (rT1-T2) and locally advanced (rT3-T4) stages of recurrent laryngeal SCC. For comparisons, we performed the meta-analyses with the odds ratios (ORs), and 2-sided p-values < 0.05 were considered significant. The analyses were conducted with OpenMetaAnalyst (version 6) and SPSS version 20 (IBM SPSS). To evaluate potential publication bias, we used a weighted linear regression and a modified Macaskill's test, which provides more balanced type I error rates in the tail probability areas relative to other publication bias tests . GR conducted the statistical analyses.

Limitations

This systematic review and meta-analysis has some limitations that need to be addressed. We included only full papers in the English language and excluded abstracts. Moreover, all of the included studies were retrospective. We observed substantial heterogeneity (I2 > 50%) according to the Cochrane guidelines in 4 of 10 outcomes considered.

Results

Study selection

We identified 276 references. One hundred eight-seven papers were excluded after reading the titles, and 70 were excluded after reading the abstracts. We analysed 19 retrospective studies in full paper format because no prospective or randomised studies were found. Fourteen references including 291 patients fulfilled our search criteria - - . Six of these studies involved mixed series because they included patients who underwent primary SCL and salvage SCL after RT failure. The remaining eight papers focused only on salvage surgeries. Five references were excluded, including 3 mixed series whose authors reported only the cumulative data for the series, one paper that was not available and one study that included other surgical techniques. Figure 1 illustrates the study selection process.
Fig. 1.

We identified 276 references. One hundred eight-seven papers were excluded after reading the title, and 70 were excluded after reading the abstracts. We analysed 19 retrospective studies in full paper format. Fourteen references including 291 patients fulfilled our search criteria. Five references were excluded, including 3 mixed series whose authors reported only the cumulative data of the series, one paper that was not available and one that included other surgical techniques.

We identified 276 references. One hundred eight-seven papers were excluded after reading the title, and 70 were excluded after reading the abstracts. We analysed 19 retrospective studies in full paper format. Fourteen references including 291 patients fulfilled our search criteria. Five references were excluded, including 3 mixed series whose authors reported only the cumulative data of the series, one paper that was not available and one that included other surgical techniques.

Characteristics of studies included

The 14 papers included 291 adult patients. The 5-year OS and 5-year DFS were reported in all papers with the exceptions of Farrag et al. , Pellini et al. and de Vincentiis . For the papers of Sperry et al. , Nakayama et al. , Deganello et al. , Leon et al. and Marchese-Ragona et al. , it was possible to extract these data from the text. All papers with the exceptions of Leone et al. and Nakayama et al. reported the short-term post-operative recovery outcomes, and Sperry et al. and Pellini et al. reported only the cumulative data for their series. The main characteristics of the studies included are reported in Table I.
Table I.

Main characteristics of the included studies (R: retrospective, NA: not available, RT: radiotherapy, CHP: cricohyoidopexy, CHEP: cricohyoidoepiglottopexy, +A: arytenoidectomy, NGT: nasogastric tube, PEG: percutaneous endoscopic gastrostomy).

Author, Year Study Type SurrtgeryPatients (n)Age (mean, range) in yearsSex (male, female)Clinical Stage after RTType of SurgeryFollow-Up Period (mean, range) in months5-year Overall Survival5-year Disease Free SurvivalDecannulation in daysNGT or PEG removal in days
De Vincentiis, 2015 R RT and laser failure20NANANANANANANA38, 28-8025, 20-39
Leone, 2014 R primary and RT failure460, 57-654 maler T1b (1), rT2 (3)CHP (3), CHEP (1)41, 12-6050%50%NANA
Sperry, 2013 R primary and RT failure4260, 34-7937 male, 5 femalerT1a (10), rT1b (13), rT2 (12), rT3 (61), rT4 (1)CHP or CHEP73, 0-20795%90.5%NANA
Nakayama, 2013Rprimary and RT failure306229 male, 1 femalerpT1 (5), rpT2 (13), rpT3 (9), rpT4 (3)CHEP (30)NA81%96.6%NANA
Luna-Ortiz, 2009RRT failure867, 43-876 male, 2 femalerT1 (4), rT2 (4)CHEP + A (3), CHEP (5)44, 20-6750%50%16, 3-5616, 3-60
Deganello, 2008RRT failure3160.1, 40- 7229 male, 2 femalerT1a (1), rT1b (5), rT2 (16), rT3 (4), rT3 (5)CHEP 8, CHP 2345, 6-18060%71%27, 14-5930, 12-72
Pellini, 2008RRT failure7859.6, 33- 7678 malerT1a (6), rT1b (30), rT2 (33), 8 rT3, 1 rT4aCHEP + A (33), CHEP (29), CHP + A (8), CHP (8)70, 10- 30081.8%95.5%176.5, 12-36515, 12-90
Leon, 2007RRT failure954.4, 43- 679 malerT1a (5), rT1b (2), rT2 (1), rT2 (1)CHEP (5), CHEP + A (1), CHP (3)mean NA, 4-12078%89%11, 6-6027, 16-40
Farrag, 2007Rprimary and RT failure10NANArT1 (1), rT2 (7), rT3 (2)NANANANA52, 19-12390, 30- 210
Pellini, 2006Rprimary and RT failure17NANAr T1a (4), rT1b (3), rT2 (8), rT2 (1), rT3 (1)CHPNANANA21.7, 6-65NA
Sewnaik, 2006RRT failure14mean NA, 49-7912 male, 2 femalerTis (1), T1 (6), T2 (7)CHEP 1416, 3-4192.8%85.7%176.5, 12-36545, 10- 120
Clark, 2005RRT failure6mean NA, 51-64NArT1a (2), rT1b (1), rT2 (3)CHEP (4), CHP (2)19, range NA72%100%9, 6-13165, 60- 300
Marchese, 2005RRT failure764, 55-727 malerT2 (6), rT3 (1)CHP (7)122, 72- 17386%86%NA42, 20- 130
Spriano, 2002RRT failure1565.2, 58- 6315 malerT1a (4), rT1b (3), rT2 (6), rT2 (1)CHEP (7), CHEP + A (4), CHP (3), CHP + A (1)63.5, 36- 10480%93.3%21.7, 6-6523.2, 12- 48
Main characteristics of the included studies (R: retrospective, NA: not available, RT: radiotherapy, CHP: cricohyoidopexy, CHEP: cricohyoidoepiglottopexy, +A: arytenoidectomy, NGT: nasogastric tube, PEG: percutaneous endoscopic gastrostomy).

Definitions of oncological and functional outcomes

The oncological outcomes were calculated from the date of surgery. The endpoint for OS was the date of death regardless of cause, whereas the endpoint for DFS was date of recurrence (local, locoregional or metastatic). For the evaluations of short-term postoperative recovery, the outcomes included the mean time until decannulation and the mean time until NGT or PEG removal.

Primary outcome

The 5-year OS was 80.2% (CI 0.719-0.885; I2 = 62%; p = 0.003), and the corresponding Forest plot is shown in Figure 2.
Fig. 2.

Forrest plot of 5-year OS for patients treated with supracricoid laryngectomy after radiation therapy failure. Weights: Leone 2014: 2.5%, Sperry 2013 16.9%, Nakayama 2013: 12%, Luna-Ortiz 2009: 4.4%, Deganello 2008: 10.4%, Pellini 2008: 15.7%, Leon 2007: 6.2%, Sewanaik 2006: 12.5%, Clark 2005: 3.8%, Marchese 2005: 6.6%, Spriano 2002: 8.9%.

Forrest plot of 5-year OS for patients treated with supracricoid laryngectomy after radiation therapy failure. Weights: Leone 2014: 2.5%, Sperry 2013 16.9%, Nakayama 2013: 12%, Luna-Ortiz 2009: 4.4%, Deganello 2008: 10.4%, Pellini 2008: 15.7%, Leon 2007: 6.2%, Sewanaik 2006: 12.5%, Clark 2005: 3.8%, Marchese 2005: 6.6%, Spriano 2002: 8.9%. Figure 3 (upper box) shows the Forest plot for 5-year OS for T1-T2 (early stage according to TNM classification 31) patients (proportion: 0.798; CI 0.686-0.911; I2 = 35%; p = 0.167). The middle box shows the Forest plot for 5-year OS of T3-T4 patients (locally advanced stage; proportion: 0.923; CI 0.806-1.041; I2 = 0%; p = 0.697). The lower box depicts the Forest plot for 5-year OS for early vs locally advanced SCC patients (OR: 0.670; CI 0.117- 3.855; I2 = 7%; p = 0.340).
Fig. 3.

Upper box: Forest plot of 5-year OS for patients affected with "early" T1-T2 recurrent laryngeal cancer after radiation therapy failure who were treated with supracricoid laryngectomy. Weights: Leone 2014: 4.8%, Sperry 2013 37.3%, Deganello 2008: 20.1%, Clark 2005: 7.6%, Marchese 2005: 11.1%, Spriano 2002: 19.1%.Middle box: Forest plot of the 5-year OS for patients affected with "locally advanced" T3-T4 recurrent laryngeal cancer following radiation therapy RT failure who were treated with SCL. Weights: Sperry 2013 20.6%, Deganello 2008: 75.6%, Marchese 2005: 3.8%. Lower box: Forest plot of the 5-year OS for patients affected with "early" vs. "locally advanced" recurrent laryngeal cancer following radiation therapy failure who were treated with supracricoid laryngectomy. Weights: Sperry 2013 43.4%, Deganello 2008: 32%, Marchese 2005: 21.6%.

Upper box: Forest plot of 5-year OS for patients affected with "early" T1-T2 recurrent laryngeal cancer after radiation therapy failure who were treated with supracricoid laryngectomy. Weights: Leone 2014: 4.8%, Sperry 2013 37.3%, Deganello 2008: 20.1%, Clark 2005: 7.6%, Marchese 2005: 11.1%, Spriano 2002: 19.1%.Middle box: Forest plot of the 5-year OS for patients affected with "locally advanced" T3-T4 recurrent laryngeal cancer following radiation therapy RT failure who were treated with SCL. Weights: Sperry 2013 20.6%, Deganello 2008: 75.6%, Marchese 2005: 3.8%. Lower box: Forest plot of the 5-year OS for patients affected with "early" vs. "locally advanced" recurrent laryngeal cancer following radiation therapy failure who were treated with supracricoid laryngectomy. Weights: Sperry 2013 43.4%, Deganello 2008: 32%, Marchese 2005: 21.6%.

Secondary outcomes

The 5-year DFS was 89.5% (CI 0.838-0.952; I2 = 52%; p = 0.022) as illustrated in Figure 4. Figure 5 (upper box) displays the Forest plot for the 5-year DFS of the T1-T2 patients (early stage; proportion: 0.869; CI 0.792-0.946; I2 = 15%; p = 0.315). The middle box presents the Forest plot for the 5-year DFS of the T3-T4 patients (locally advanced stage; proportion: 0.911; CI 0.784-1.037; I2 = 0%; p = 0.812). The lower box shows the Forest plot for the 5-year DFS of early vs. locally advanced stage patients (OR: 0.475; CI 0.093-2.430; I2 = 0%; p = 0.841).
Fig. 4.

Forest plot of the 5-year DFS for patients who were treated with supracricoid laryngectomy after radiation therapy failure. Weights: Leone 2014: 1.3%, Sperry 2013 15%, Nakayama 2013: 18.2%, Luna-Ortiz 2009: 2.4%, Deganello 2008: 8.3%, Pellini 2008: 20.8%, Leon 2007: 5.8%, Sewanaik 2006: 6.8%, Clark 2005: 6.5%, Marchese 2005: 4%, Spriano 2002: 10.9%.

Fig. 5.

Upper box: Forest plot of the 5-year DFS for patients affected with "early" T1-T2 recurrent laryngeal cancer after radiation therapy failure who were treated with supracricoid laryngectomy. Weights: Leone 2014: 2.4%, Sperry 2013 35.3%, Deganello 2008: 14.6%, Clark 2005: 14%, Marchese 2005: 6.2%, Spriano 2002: 27.4%. Middle box: Forest plot of the 5-year DFS for patients affected with "locally advanced" T3-T4 recurrent laryngeal cancer after radiation therapy failure who were treated with supracricoid laryngectomy. Weights: Sperry 2013 57.3%, Deganello 2008: 38.2%, Marchese 2005: 4.5%. Lower box: Forest plot of the 5-year DFS for patients affected with "early" vs. "locally advanced" recurrent laryngeal cancer following after radiation therapy failure who were treated with supracricoid laryngectomy. Weights: Sperry 2013 29%, Deganello 2008: 51.3%, Marchese 2005: 19.7%.

Forest plot of the 5-year DFS for patients who were treated with supracricoid laryngectomy after radiation therapy failure. Weights: Leone 2014: 1.3%, Sperry 2013 15%, Nakayama 2013: 18.2%, Luna-Ortiz 2009: 2.4%, Deganello 2008: 8.3%, Pellini 2008: 20.8%, Leon 2007: 5.8%, Sewanaik 2006: 6.8%, Clark 2005: 6.5%, Marchese 2005: 4%, Spriano 2002: 10.9%. Upper box: Forest plot of the 5-year DFS for patients affected with "early" T1-T2 recurrent laryngeal cancer after radiation therapy failure who were treated with supracricoid laryngectomy. Weights: Leone 2014: 2.4%, Sperry 2013 35.3%, Deganello 2008: 14.6%, Clark 2005: 14%, Marchese 2005: 6.2%, Spriano 2002: 27.4%. Middle box: Forest plot of the 5-year DFS for patients affected with "locally advanced" T3-T4 recurrent laryngeal cancer after radiation therapy failure who were treated with supracricoid laryngectomy. Weights: Sperry 2013 57.3%, Deganello 2008: 38.2%, Marchese 2005: 4.5%. Lower box: Forest plot of the 5-year DFS for patients affected with "early" vs. "locally advanced" recurrent laryngeal cancer following after radiation therapy failure who were treated with supracricoid laryngectomy. Weights: Sperry 2013 29%, Deganello 2008: 51.3%, Marchese 2005: 19.7%. The mean time until decannulation was 35.6 days (CI 24.3-46.9; I2 = 95%; p < 0.001), and the corresponding Forest plot is presented in Figure 6. The mean time until NGT or PEG removal was 28.3 days (CI 22.7-33.8; I2 = 86%; p <= 0.001; Fig. 7).
Fig. 6.

Forest plot of the mean time until decannulation (days) for patients who were treated with supracricoid laryngectomy after radiation therapy failure. Weights: Luna-Ortiz 2009: 6.5%, Deganello 2008: 12.2%, Pellini 2008: 8.2%, Leon 2007: 11.5%, Farrag 2007: 9.9%, Pellini 2006: 11.8%, Sewanaik 2006: 3.2%, Clark 2005: 12.3%, Spriano 2002: 11.8%, de Vincentiis 2015: 12%.

Fig. 7.

Forest plot of the mean time until NGT or PEG removal (days) for patients who were treated with supracricoid laryngectomy after radiation therapy failure. Weights: Luna-Ortiz 2009: 10.5%, Deganello 2008: 13.9%, Pellini 2008: 14.5%, Leon 2007: 14.7%, Farrag 2007: 3.1%, Sewanaik 2006: 7.6%, Clark 2005: 0.3%, Marchese 2005: 5%, Spriano 2002: 14.3%, de Vincentiis 2015: 15.5%.

Forest plot of the mean time until decannulation (days) for patients who were treated with supracricoid laryngectomy after radiation therapy failure. Weights: Luna-Ortiz 2009: 6.5%, Deganello 2008: 12.2%, Pellini 2008: 8.2%, Leon 2007: 11.5%, Farrag 2007: 9.9%, Pellini 2006: 11.8%, Sewanaik 2006: 3.2%, Clark 2005: 12.3%, Spriano 2002: 11.8%, de Vincentiis 2015: 12%. Forest plot of the mean time until NGT or PEG removal (days) for patients who were treated with supracricoid laryngectomy after radiation therapy failure. Weights: Luna-Ortiz 2009: 10.5%, Deganello 2008: 13.9%, Pellini 2008: 14.5%, Leon 2007: 14.7%, Farrag 2007: 3.1%, Sewanaik 2006: 7.6%, Clark 2005: 0.3%, Marchese 2005: 5%, Spriano 2002: 14.3%, de Vincentiis 2015: 15.5%.

Publication bias

No publication bias was detected according to Macaskill's modified test.

Discussion

In most centres in northern Europe and North America, radiotherapy is the primary treatment for patients with early laryngeal SCC . RT is a well-established treatment for selected laryngeal carcinomas that elicits good oncologic and functional results. The reported failure rates range between 9-21% for T1 and 28-37% for T2 glottic carcinomas. In supraglottic laryngeal cancer, the reported failure rates for T1 and T2 lesions are 24-30% and 25%-45%, respectively . Re-irradiation protocols (in combination with radio-sensitising agents) are at significant risk for morbidity and remain investigational; they may be considered for patients with unresectable locoregional disease. Therefore, surgery is the preferred modality for curative treatment of recurrent laryngeal cancer after failure of nonsurgical treatments. There are three options for salvage surgery after radiation failure: total laryngectomy, transoral laser microsurgery (TLM) and open partial laryngectomy. Total laryngectomy is widely considered the classic approach to glottic SCC recurrence after irradiation 36, but considerably impairs the quality of life primarily due to the permanent tracheostoma and the loss of voice 9. Compared with alternative treatment options for laryngeal cancer, the oncological outcomes of TLM are inferior to those of open partial laryngectomy. TLM has a relatively lower mean larynx preservation rate of 72.3% versus 84% for open partial laryngectomy, which reflects a higher locoregional failure rate after TLM . In the radio-recurrent setting, open partial laryngectomies have been less commonly used in the past due to concerns about unpredictable spreading and the postoperative function of the irradiated organ as well as a higher risk of complications . The correct assessment of tumour extension of a recurrent laryngeal carcinoma may be difficult due to the residual inflammatory or functional changes associated with radiation therapy. Many recurrences present with multicentric tumour foci that are localised below intact mucosa and further masked by post-treatment oedema and fibrosis . This pathological phenomenon that results in clinically significant difficulties in correctly restaging the tumour after irradiation justify the classical choice of salvage total laryngectomy in cases of carcinoma recurrence following radiotherapy failure . There have been several reports about the effectiveness of open partial laryngectomies in terms of survival and functional results in residual or recurrent cancer. To our knowledge, this is first systematic review and meta-analysis to examine the oncological outcomes according to T stage and short-term postoperative recovery outcomes of SCL for treatment of laryngeal SCC after RT failure. This systematic review and meta-analysis resulted in the following findings: 1) 5-year OS was 80.2%; 2) 5-year DFS was 89.5%; 3) mean time until decannulation was 35.6 days; and 4) mean time until NGT or PEG removal was 28.3 days. The studies included in this meta-analysis share a common trait, i.e., the strict criteria for patient selection for candidacy for SCL after RT failure . The indications and contraindications after the failure of RT are similar to those that have been specified for patients with previously untreated laryngeal tumours . Therefore, we hypothesise that careful assessment of tumour extension might be responsible for the high 5-year OS and 5-year DFS. In our sub-analysis, we found that 5-year OS for T1-T2 patients (early stage) was 79.8%; interestingly, this rate was 92.3% for T3-T4 patients (locally advanced stage). The 5-year DFS was 86.9% for T1-T2 patients and 91.1% for T3-T4 patients. These data might be attributable to inaccurate staging (i.e., understaging) prior to salvage surgery. In this regard, Zbaren et al. reported that 52% of patients were clinically understaged and that the diagnostic accuracy of clinical evaluation (via fiberoptic laryngoscopy, CT, MRI, or microlaryngoscopic examination findings) was only 38%. Nevertheless, our statistical analysis demonstrated that the differences between the 5-year OS and DFS of early and locally advanced SCC patients were not significantly different (p = 0.340 and p = 0.841, respectively). However, these results may have been influenced by the small size of the locally advanced stage group (only 17 patients). Some of the papers included in this meta-analysis - reported only clinical TNM. We strongly believe that future studies should also report pathological stage after salvage surgery. The theoretical advantage of SCL over TL is that at least one functioning crico-arytenoid joint is maintained, and thus a permanent tracheostoma is not required, and the main laryngeal functions (i.e., respiration, phonation and swallowing) are preserved. Nevertheless, swallowing impairment represents the main functional issue due to the modification of the hypopharyngo/laryngeal anatomy. This condition has implications for the quality of life in addition to an association with potentially life threatening complications, such as aspiration pneumonia . This meta-analysis demonstrated that the mean time until NGT or PEG removal was 28.3 days, and the mean time until decannulation was 35.6 days. These data accord with the reports of other authors who prefer the initial removal of the NGT and initiation of oral alimentation with a tracheostomy tube to protect and clean the airways and permit the suction of any residual food that may be present . However, the proper postoperative management of tracheostomies is still under debate. In contrast, different authors - have proposed early removal of the tracheostomy tube to ensure a rapid mobilisation of the residual larynx to avoid any interference with the cough reflex, which limits the incidence of pulmonary infection . These different approaches might be due to personal experience or the preferences of the surgeon. Some authors have suggested that, in consideration of the possibility of long-lasting swallowing disorders, clinicians should consider preoperative PEG in patients undergoing SCL as a salvage surgery for glottic carcinoma after irradiation failure. This suggestion is consistent with the opinion of the majority of the authors of the studies included in the present meta-analysis . SCLs allow for satisfactory functional results, but surgical protocols need to be followed by adequate nursing and rehabilitation protocols. However, there is no evidence regarding when rehabilitation should be initiated, which criteria should be adopted to indicate the initiation and termination of rehabilitation, or which voice and swallowing rehabilitation procedures provide the optimal functional outcomes . Therefore, we recommend that future work should focus on standardising postoperative care and rehabilitation protocols.

Conclusions

Recurrent laryngeal cancer after irradiation is a difficult clinical problem. Although total laryngectomy has been widely considered for many years to be the treatment of choice, this meta-analysis demonstrated that supracricoid laryngectomy for recurrent laryngeal cancer after chemoradiotherapy provides reliable oncological and short-term postoperative recovery outcomes.
  52 in total

1.  Subtotal laryngectomy: outcomes of 469 patients and proposal of a comprehensive and simplified classification of surgical procedures.

Authors:  G Rizzotto; E Crosetti; M Lucioni; G Succo
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-06       Impact factor: 2.503

2.  [Technical indications and results of reconstructive laryngectomies].

Authors:  L Traissac; J Verhulst
Journal:  Rev Laryngol Otol Rhinol (Bord)       Date:  1991

3.  Supracricoid partial laryngectomies after failure of radiation therapy.

Authors:  Marc Makeieff; Delphine Venegoni; Guisepe Mercante; Louis Crampette; Bernard Guerrier
Journal:  Laryngoscope       Date:  2005-02       Impact factor: 3.325

4.  Supracricoid laryngectomy outcomes: The Johns Hopkins experience.

Authors:  Tarik Y Farrag; Wayne M Koch; Charles W Cummings; David Goldenberg; Peter M Abou-Jaoude; Joseph A Califano; Paul W Flint; Kimberly Webster; Ralph P Tufano
Journal:  Laryngoscope       Date:  2007-01       Impact factor: 3.325

5.  Complications and functional outcome after supracricoid partial laryngectomy with cricohyoidoepiglottopexy.

Authors:  P Naudo; O Laccourreye; G Weinstein; V Jouffre; H Laccourreye; D Brasnu
Journal:  Otolaryngol Head Neck Surg       Date:  1998-01       Impact factor: 3.497

6.  Supracricoid partial laryngectomy: analyses of oncologic and functional outcomes.

Authors:  Ercan Pinar; Abdulkadir Imre; Caglar Calli; Semih Oncel; Huseyin Katilmis
Journal:  Otolaryngol Head Neck Surg       Date:  2012-08-11       Impact factor: 3.497

7.  Validation of an instrument to measure voice-related quality of life (V-RQOL).

Authors:  N D Hogikyan; G Sethuraman
Journal:  J Voice       Date:  1999-12       Impact factor: 2.009

8.  Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.

Authors:  Sharon A Spencer; Jonathan Harris; Richard H Wheeler; Mitchell Machtay; Christopher Schultz; William Spanos; Marvin Rotman; Ruby Meredith; Kie-Kian Ang
Journal:  Head Neck       Date:  2008-03       Impact factor: 3.147

9.  Local control after supracricoid partial laryngectomy for "advanced" endolaryngeal squamous cell carcinoma classified as T3.

Authors:  Xavier Dufour; Stéphane Hans; Erwan De Mones; Daniel Brasnu; Madeleine Ménard; Ollivier Laccourreye
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-09

10.  Supracricoid laryngectomies: oncological and functional results for 152 patients.

Authors:  C A Leone; P Capasso; G Russo; P D'Errico; P Cutillo; P Orabona
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-10       Impact factor: 2.124

View more
  2 in total

Review 1.  [Integrity of swallowing apparatus-past, present, and future].

Authors:  A O H Gerstner; W Laffers
Journal:  HNO       Date:  2021-01-12       Impact factor: 1.284

2.  Effect of neuromuscular electrical stimulation for fatigue management in patients with advanced laryngeal cancer receiving chemoradiotherapy.

Authors:  Mei-Jia Zhang; Ji-Wei Mu; Xiu-Sheng Qu; Chong Feng; Wei Zhao
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.